Feed RCUS
RC

Arcus Biosciences, Inc. RCUS · NYSE

$18.18 -2.31% (-$0.43)

Market cap
$2.29B
Enterprise value
$2.25B
P/E
-
Forward P/E
-
PEG
-
P/S
19.5x
P/FCF
-
EV/EBITDA
-
ROIC
-65.8%
Bruto marža
94.0%
Neto marža
-386.3%
Dividend yield
-
Payout ratio
-
Neto dolg/EBITDA
-
Beta
0.81
Free float
74.9%

O podjetju

Arcus Biosciences, Inc. (RCUS) is an American biotechnology company focused on researching and developing new drugs for the treatment of oncology and inflammatory diseases. The company specializes in discovering innovative therapeutic drugs based on immunotherapy and cell growth pathway inhibition. Its research and development efforts are aimed at boosting the immune system's ability to fight against cancer cells and inflammatory processes. Arcus Biosciences collaborates with pharmaceutical companies and academic institutions in the discovery and development of new drugs and therapies. The company aims to bring innovative treatment options to patients facing challenging and difficult-to-treat diseases. Arcus Biosciences, Inc. is recognized for its research potential and influential position in the field of immuno-oncology. Arcus Biosciences, Inc. (RCUS) shares may represent an attractive investment opportunity for investors monitoring the biotechnology sector and seeking investments in a company with an innovative portfolio of research in oncology and immunotherapy.

Sector

Healthcare

Industry

Biotechnology

CEO

Terry J. Rosen

Employees

601

Headquarters

Hayward

Vrednotenje

Je današnja cena primerna?

  • Kaj govori v prid: Cena delnice je pod Bulios Fair Price.

Rast in ocene

Ali podjetje raste in kaj sledi?

  • Kaj govori v prid: Prihodki so v zadnjih 3 letih rasli za 30 % letno.
  • Na kaj bodite pozorni: Analitiki v tem poslovnem letu pričakujejo padec prihodkov za 70 %.

Donosnost in kakovost

Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?

  • Na kaj bodite pozorni: Podjetje je v zadnjih 12 mesecih poslovalo z izgubo.

Finančno zdravje

Ali zmore svoj dolg?

  • Kaj govori v prid: Ima več denarja kot dolga: $150,0M proti $114,0M.
  • Na kaj bodite pozorni: V testu finančnega zdravja (Piotroski) izpolni le 0 od 9 točk.

Kapital in dividende

Kaj podjetje počne z zasluženim denarjem?

Analitiki

Kaj menijo strokovnjaki in ali se to spreminja?

Lastniki in insajderji

Kdo ima delnice in kaj počne vodstvo?

Segmenti

Kateri del podjetja raste?

Primerjava s konkurenco

Kako se primerja s podobnimi podjetji?

Cena in tveganje

Kako se delnica obnaša?

Izkazi

Vse številke

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe.